Tozasertib (VX-680, MK-0457)

Catalog No.S1048

Molecular Weight(MW): 464.59

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with K_i_app of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.

Cited by 53 Publications

Nature, 2018, 559(7713):211-216

PubMed: 29973724 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Cell, 2010, 142(3):444-55

PubMed: 20691903 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):1004-1010

PubMed: 30080692 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):153-66

PubMed: 27138904 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):819-26

PubMed: 27373675 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(1):212-8

PubMed: 27003257 ( click the link to review the publication )

Exp Hematol, 2016, 44(3):189-93

PubMed: 26706195 ( click the link to review the publication )

Tumour Biol, 2016, 37(11):14745-14755

PubMed: 27629142 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5338-48

PubMed: 26152738 ( click the link to review the publication )

Oncol Rep, 2015, 34(2):803-10

PubMed: 26044736 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

J Mol Cell Biol, 2014, 6(3):240-54

PubMed: 24847103 ( click the link to review the publication )
Biochim Biophys Acta, 2014, 1843(5):934-44

PubMed: 24480460 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2014, 307(2):L173-85

PubMed: 24838752 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

Oncol Lett, 2014, 7(1):121-124

PubMed: 24348832 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7498-511

PubMed: 25115395 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Mol Cancer Res, 2013, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1235-46

PubMed: 23321637 ( click the link to review the publication )

J Cell Mol Med, 2013, 17(2):265-76

PubMed: 23301855 ( click the link to review the publication )

Vet Comp Oncol, 2013, 10.1111/vco.12018

PubMed: 23410058 ( click the link to review the publication )

Eur J Cancer, 2012, 48(15):2417-30

PubMed: 22244830 ( click the link to review the publication )

Oncogene, 2012, 31(31):3584-96

PubMed: 22120720 ( click the link to review the publication )

J Med Chem, 2012, 55(17):7392-416

PubMed: 22803810 ( click the link to review the publication )

Brain Pathol, 2012, 23(3):244-53

PubMed: 22971244 ( click the link to review the publication )

J Neurosci, 2012, 32(32):11050-66

PubMed: 22875938 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1217-28

PubMed: 22306067 ( click the link to review the publication )

Biochem J, 2012, 447(1):93-102

PubMed: 22784093 ( click the link to review the publication )

Exp Cell Res, 2012, 318(4):336-49

PubMed: 22197704 ( click the link to review the publication )

Cytoskeleton, 2012, 69(10):840-53

PubMed: 22887753 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )
Curr Biol, 2011, 21(16):1356-65

PubMed: 21820309 ( click the link to review the publication )

Cancer Res, 2011, 71(23):7207-15

PubMed: 21978935 ( click the link to review the publication )

J Biol Chem, 2011, 286(42):36304-15

PubMed: 21878642 ( click the link to review the publication )

Biochem J, 2011, 440(1):85-93

PubMed: 21774789 ( click the link to review the publication )

Mol Cancer Ther, 2010, 9(5):1318-27

PubMed: 20388735 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description

Targets

Aurora A ^[1] (Cell-free assay)	Aurora C ^[1] (Cell-free assay)	Aurora B ^[1] (Cell-free assay)	FLT3 ^[4] (Cell-free assay)	Bcr-Abl ^[4] (Cell-free assay)
0.6 nM(Ki app)	4.6 nM(Ki app)	18 nM(Ki app)	30 nM(Ki)	30 nM(Ki)

In vitro

Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150 nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12 hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. ^[2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BE-13	NV\RZnNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jv[2lEPTB;MD6wNFM{QCEQvF2=	NFnFVohUSU6JUlXS
RS4-11	NH7kUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TwSWlEPTB;MD6wNFQxPCEQvF2=	MkjJV2FPT1KHUh?=
MFH-ino	NXLhdnZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMEC5PUDPxE1?	MnfrV2FPT1KHUh?=
NTERA-S-cl-D1	MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHOwRndKSzVyPUCuNFE1OzRizszN	MYrTRW5IWkWU
697	M3X6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{j2WmlEPTB;MD6wNlQ4OSEQvF2=	MW\TRW5IWkWU
NALM-6	NEnycY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHz1TYRKSzVyPUCuNFI2PTJizszN	NVjIOVl[W0GQR2LFVi=>
ES8	M3jHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LPV2lEPTB;MD6wOFYyOyEQvF2=	M32ybHNCVkeURWK=
HUTU-80	M3PiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo[2TWM2OD1yLkC1Nlk6KM7:TR?=	M2fKXnNCVkeURWK=
MV-4-11	NUnSXoRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMEe3PFIh\|ryP	MkjoV2FPT1KHUh?=
MONO-MAC-6	M{TncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHCSppKSzVyPUCuNFc5PzlizszN	NFHDR2xUSU6JUlXS
LC-2-ad	MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMEi3PFkh\|ryP	M36xeHNCVkeURWK=
BL-41	M2\5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXsO3dGUUN3ME2wMlExPDR3IN88US=>	NEnZNHdUSU6JUlXS
A4-Fuk	M4nXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofvTWM2OD1yLkGxOVY{KM7:TR?=	M2jhWXNCVkeURWK=
SW954	M2XRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwMUKyNlkh\|ryP	NUHJNW1DW0GQR2LFVi=>
BV-173	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPXPGJKSzVyPUCuNVI3PDFizszN	MkKwV2FPT1KHUh?=
TE-11	NVn1dFI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7NTWM2OD1yLkG0PVgzKM7:TR?=	NXXTXlFrW0GQR2LFVi=>
SK-UT-1	M2LxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;lfWpWUUN3ME2wMlE2QTZ3IN88US=>	NUC3Xmc6W0GQR2LFVi=>
SIG-M5	NULm[Y97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jhVWlEPTB;MD6xOlcxPyEQvF2=	MXnTRW5IWkWU
OCUB-M	NX21TW5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;wTWM2OD1yLkG2PVg{KM7:TR?=	MV;TRW5IWkWU
K052	MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVy2V3Y3UUN3ME2wMlE6PDhizszN	NYm3W2tRW0GQR2LFVi=>
VA-ES-BJ	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rhW2lEPTB;MD6yNFA5PiEQvF2=	NIrU[GVUSU6JUlXS
SW982	MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjDNI1KSzVyPUCuNlE{QCEQvF2=	M{ji[HNCVkeURWK=
LB647-SCLC	M1nZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTi[ZhKSzVyPUCuNlE2OjNizszN	M1zqOXNCVkeURWK=
PSN1	M1nadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPTcoZKSzVyPUCuNlIxOjZizszN	MXnTRW5IWkWU
BB30-HNC	M17wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fsfGlEPTB;MD6yNlU6OSEQvF2=	MUPTRW5IWkWU
ST486	NWLDeHZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLnTWM2OD1yLkKzNFg4KM7:TR?=	NVzHTnd5W0GQR2LFVi=>
MOLT-4	M4HsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwMkOzN\|ch\|ryP	NYr6VY55W0GQR2LFVi=>
EW-16	NWS5[\|llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXaSWtKSzVyPUCuNlM4PjhizszN	NX7wXpBbW0GQR2LFVi=>
KS-1	M4nrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3EToU2UUN3ME2wMlI{Pzh3IN88US=>	M{nFcHNCVkeURWK=
SR	NEHuUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMkS1OlQh\|ryP	MVHTRW5IWkWU
KM12	NFzObnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DWV2lEPTB;MD6yOlM3KM7:TR?=	M2K3[HNCVkeURWK=
EM-2	NID2[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwMk[2OFEh\|ryP	MnK3V2FPT1KHUh?=
MEG-01	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1L5U2lEPTB;MD6yO\|g1QSEQvF2=	M4SyZ3NCVkeURWK=
NB13	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjvVnRKSzVyPUCuNlc6QDRizszN	M3fBSnNCVkeURWK=
RKO	NXvvRVFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUL3WFBxUUN3ME2wMlMxQDF\|IN88US=>	M1\j[HNCVkeURWK=
CESS	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwM{GzNlgh\|ryP	NUK1ZZFUW0GQR2LFVi=>
EoL-1-cell	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jZS2lEPTB;MD6zN\|Q2QSEQvF2=	NH72UFdUSU6JUlXS
DOHH-2	NFjVZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYr2XGpmUUN3ME2wMlM{PzhzIN88US=>	Ml;LV2FPT1KHUh?=
A388	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXHUXNkUUN3ME2wMlM1ODh4IN88US=>	M{jHR3NCVkeURWK=
LAMA-84	M2fYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4[zR2lEPTB;MD6zOVE4QCEQvF2=	NIT3[oZUSU6JUlXS
IMR-5	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HZVGlEPTB;MD6zOVU1KM7:TR?=	M{nnbnNCVkeURWK=
KARPAS-422	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkH4TWM2OD1yLkO3NlczKM7:TR?=	M2m1eXNCVkeURWK=
MRK-nu-1	MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nZRWlEPTB;MD6zPFE{KM7:TR?=	M1XiNHNCVkeURWK=
BL-70	MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3wPVJKSzVyPUCuN\|g6PzRizszN	M1Ox[nNCVkeURWK=
LXF-289	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPUXYRKSzVyPUCuOFA1ODZizszN	M2DWTnNCVkeURWK=
RL95-2	M{TFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7LV\|FKSzVyPUCuOFA2PjdizszN	NEC3VnZUSU6JUlXS
QIMR-WIL	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnmXmdKSzVyPUCuOFI3PzZizszN	M2C4RXNCVkeURWK=
K-562	M3TqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXj2SohNUUN3ME2wMlQ{PDd{IN88US=>	MVvTRW5IWkWU
NCI-H510A	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwNEO4NlMh\|ryP	MkP2V2FPT1KHUh?=
NCI-H524	Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPLcXhKSzVyPUCuOVEyPDdizszN	M2PhN3NCVkeURWK=
KE-37	MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nBVGlEPTB;MD61NlExOiEQvF2=	MWHTRW5IWkWU
KP-N-YS	M3O2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fINmlEPTB;MD61OFM6OiEQvF2=	NFLGRZNUSU6JUlXS
LS-411N	M4nSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzITWM2OD1yLkW3O\|UzKM7:TR?=	MnyzV2FPT1KHUh?=
CTV-1	M13GWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvUTVkyUUN3ME2wMlU5Pzd\|IN88US=>	NV;Tb3p7W0GQR2LFVi=>
NCI-SNU-16	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXEe2FLUUN3ME2wMlY{PTdzIN88US=>	NY\rbGprW0GQR2LFVi=>
HT-144	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3myemlEPTB;MD62N\|c6QCEQvF2=	Mnj6V2FPT1KHUh?=
NCI-H187	MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXW4[HR{UUN3ME2wMlY1OTNizszN	MkmyV2FPT1KHUh?=
OCI-AML2	NFnmN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfN[5J[UUN3ME2wMlY1PDB\|IN88US=>	MkP4V2FPT1KHUh?=
CCRF-CEM	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33hd2lEPTB;MD62OVM1PiEQvF2=	MnPzV2FPT1KHUh?=
ONS-76	NFrDTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rmTmlEPTB;MD62OlQ2QCEQvF2=	NWixWHdDW0GQR2LFVi=>
IST-SL2	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXkNpN1UUN3ME2wMlcyQTh{IN88US=>	MoXHV2FPT1KHUh?=
NB6	M13uZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3:0XmlEPTB;MD63O\|I2PCEQvF2=	MnH0V2FPT1KHUh?=
SK-PN-DW	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTmTWM2OD1yLke5NVQh\|ryP	MYnTRW5IWkWU
HCC1599	NYHzdnJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUD1eGdrUUN3ME2wMlgxQDd2IN88US=>	Mm\iV2FPT1KHUh?=
MC116	M4jMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDJe5ZKSzVyPUCuPFUxOTFizszN	MkDIV2FPT1KHUh?=
TE-15	M4L2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTBPZViUUN3ME2wMlg2ODl6IN88US=>	NV\DUnhOW0GQR2LFVi=>
HOP-62	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwOE[zNlkh\|ryP	MmLWV2FPT1KHUh?=
TGBC24TKB	NVf6[Wk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\0emlEPTB;MD64OlM5PSEQvF2=	MojjV2FPT1KHUh?=
HCE-4	MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3PZoFKSzVyPUCuPFgxPjNizszN	Ml;TV2FPT1KHUh?=
ALL-PO	M2rETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXmbpdtUUN3ME2wMlg5OTd3IN88US=>	MWXTRW5IWkWU
KGN	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfCZ4FnUUN3ME2wMlg6QTl3IN88US=>	MknzV2FPT1KHUh?=
ML-2	M1nmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDyTWM2OD1yLkmwNlU6KM7:TR?=	NXq2[YMzW0GQR2LFVi=>
ES4	Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LPPGlEPTB;MD65NVEzQCEQvF2=	MXnTRW5IWkWU
SF126	NF;YfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwOUS4NVkh\|ryP	NIW2XpRUSU6JUlXS
SK-N-DZ	MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlK5TWM2OD1yLkm2NVg6KM7:TR?=	NHzrfWdUSU6JUlXS
HCC1187	NWjlSWt1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEGxNYxKSzVyPUGuNFA2ODVizszN	NWG5RXhsW0GQR2LFVi=>
DU-4475	NHnzdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE[2folKSzVyPUGuNFE4PTZizszN	NW\4[GVtW0GQR2LFVi=>
NKM-1	NE\tbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPBTWM2OD1zLkCyO\|c2KM7:TR?=	NFraSlhUSU6JUlXS
HL-60	M2\RSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTuTWM2OD1zLkC2OVc1KM7:TR?=	MWHTRW5IWkWU
SBC-1	NXSyZZpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnHd5ljUUN3ME2xMlEzPTR{IN88US=>	MWTTRW5IWkWU
TE-10	M3PSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{j4VmlEPTB;MT6xNlk1PiEQvF2=	MXfTRW5IWkWU
ETK-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTFwMUO2NVMh\|ryP	NEPVfI9USU6JUlXS
HAL-01	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TybmlEPTB;MT6xOlcxQSEQvF2=	M2TxSHNCVkeURWK=
BB65-RCC	Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF34RYVKSzVyPUGuNVgxODVizszN	MXnTRW5IWkWU
EW-1	NHXQSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLqTWM2OD1zLkG4OVYzKM7:TR?=	MnvFV2FPT1KHUh?=
SK-NEP-1	Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTFwMkGxNVEh\|ryP	Mn3VV2FPT1KHUh?=
SK-LMS-1	NF3RPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVn0PFZwUUN3ME2xMlIzOjF{IN88US=>	M1K1TXNCVkeURWK=
DEL	NX7NfpVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTLZ21KSzVyPUGuNlU3PDNizszN	NYnVOVYyW0GQR2LFVi=>
GT3TKB	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHr3Zm9KSzVyPUGuNlgxPTdizszN	MWjTRW5IWkWU
MOLT-16	M1mzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTXflNKSzVyPUGuN\|U1ODVizszN	NIn6TZlUSU6JUlXS
CMK	M4jPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTFwNEKxNVch\|ryP	MmjBV2FPT1KHUh?=
NB5	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLQTWM2OD1zLk[0NlI6KM7:TR?=	MXzTRW5IWkWU
NCI-H1963	M4jRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTjNJNDUUN3ME2xMlcxPTh\|IN88US=>	NHTBUYlUSU6JUlXS
KURAMOCHI	Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\ONWlEPTB;MT63PFkyOSEQvF2=	MXHTRW5IWkWU
TE-8	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\LVlVbUUN3ME2xMlgxOzZ6IN88US=>	MYrTRW5IWkWU
NCI-H1304	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTFwOEOwO\|Mh\|ryP	NYjJS3pvW0GQR2LFVi=>
A101D	NH;0fnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1iy[GlEPTB;MT64O\|M6PSEQvF2=	M2rGdXNCVkeURWK=
SCLC-21H	NF;YSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTFwOUewOVch\|ryP	M3jCZXNCVkeURWK=
GB-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvIVmxKSzVyPUKuNFE3PDdizszN	M2PLdHNCVkeURWK=
KARPAS-45	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Hp[WlEPTB;Mj6wNlY2PCEQvF2=	NWfKUZc6W0GQR2LFVi=>
ATN-1	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;lfIJOUUN3ME2yMlAzQDV6IN88US=>	MoLDV2FPT1KHUh?=
NCI-H720	NITaN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLHS2hKSzVyPUKuNFYzPDRizszN	MmjnV2FPT1KHUh?=
RPMI-6666	M4i2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTJwMU[yNFch\|ryP	M4P4VnNCVkeURWK=
NB17	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTJwMkmyO{DPxE1?	MknXV2FPT1KHUh?=
IST-SL1	M2jL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnEd5ZKSzVyPUKuNlk4PjVizszN	MlfZV2FPT1KHUh?=
SH-4	MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTJwM{K0Olkh\|ryP	MVzTRW5IWkWU
K5	MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTJwNECzNVkh\|ryP	NUfMXJNxW0GQR2LFVi=>
OVCAR-4	NHj4fldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M162dWlEPTB;Mj60OlE{KM7:TR?=	M33LWHNCVkeURWK=
ACN	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYWwOmhtUUN3ME2yMlUxOjF\|IN88US=>	NIrqRm5USU6JUlXS
TGW	NFXRVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\sOG5KSzVyPUKuOlU5OzJizszN	NGrvS3JUSU6JUlXS
NCI-H2107	NV7UTmpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXQXIFoUUN3ME2yMlg{PzFzIN88US=>	MUPTRW5IWkWU
NCI-H82	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrxW\|lKSzVyPUKuPFM5OzhizszN	MV;TRW5IWkWU
SK-N-FI	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DNXGlEPTB;Mj64Olg3QCEQvF2=	MlPZV2FPT1KHUh?=
LB1047-RCC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfVVmZUUUN3ME2yMlg5OTJ4IN88US=>	NFzvSphUSU6JUlXS
LU-134-A	MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnOWVJKSzVyPUKuPFkzPiEQvF2=	NISyRWpUSU6JUlXS
NCI-H209	NIXN[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUD4PW8xUUN3ME2yMlkyOjV\|IN88US=>	NFTwVYxUSU6JUlXS
NOMO-1	NYLXR5JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTNwMEKyO\|Qh\|ryP	M1KwRnNCVkeURWK=
RH-1	M2PW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;0dGlEPTB;Mz6xO\|I6OSEQvF2=	NVzVdlF7W0GQR2LFVi=>
LOUCY	NFjwOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;NemlEPTB;Mz6xPFY6OyEQvF2=	M13vVHNCVkeURWK=
TE-9	NYDMOIg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTNwMk[3N\|Yh\|ryP	MmTuV2FPT1KHUh?=
PF-382	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELKW5BKSzVyPUOuN\|U4PzhizszN	M{LZR3NCVkeURWK=
RPMI-8402	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPvdIV1UUN3ME2zMlU5PjB\|IN88US=>	MVvTRW5IWkWU
HEL	NEDQ[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPzSXpOUUN3ME2zMlY{OiEQvF2=	MofiV2FPT1KHUh?=
NOS-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvrTWM2OD1\|Lki0O\|U1KM7:TR?=	M4XIRnNCVkeURWK=
ES1	NF73SWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHiTWM2OD1\|LkmyNlk{KM7:TR?=	MV;TRW5IWkWU
NCI-H2171	NICwXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnUfoJOUUN3ME2zMlkzPDJ\|IN88US=>	MWXTRW5IWkWU
NCI-H747	M2\iNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\pPWlEPTB;Mz65OFIzOSEQvF2=	NVXER3lZW0GQR2LFVi=>
MHH-NB-11	M4\VZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7OXHVKSzVyPUOuPVU{OTJizszN	M3[wZ3NCVkeURWK=
MZ1-PC	NH3LdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTNwOUmyOEDPxE1?	NXWxeZROW0GQR2LFVi=>
MMAC-SF	MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nEN2lEPTB;ND6wNlQ3PyEQvF2=	M1\NZnNCVkeURWK=
NMC-G1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XvRWlEPTB;ND6yNlczOyEQvF2=	NVL0Z5pNW0GQR2LFVi=>
SW872	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jYXGlEPTB;ND6zOFM1KM7:TR?=	MWPTRW5IWkWU
TE-12	M1nSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1KxeGlEPTB;ND61OlM6PCEQvF2=	NHjhVZVUSU6JUlXS
LU-139	M2PRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnDUI5KSzVyPUSuOlE5OzVizszN	M3zDfXNCVkeURWK=
HC-1	NIW4dIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTzTWM2OD12Lk[5OFk1KM7:TR?=	M{Lj[3NCVkeURWK=
COR-L279	MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTRwN{W4PVEh\|ryP	MYXTRW5IWkWU
SF268	M1XEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXrb4JKSzVyPUSuO\|k6OTZizszN	NI\QfJFUSU6JUlXS
MC-CAR	M{HCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrXTWM2OD13LkC2O\|U4KM7:TR?=	NFvjXGhUSU6JUlXS
TK10	M3v0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmS5TWM2OD13LkO1OFY6KM7:TR?=	NYDxcWpiW0GQR2LFVi=>
TE-1	MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7QZ4hKSzVyPUWuOFkxODRizszN	NH3QOI1USU6JUlXS
NCI-H2126	NG\p[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHjVHl4UUN3ME21MlY1PTd2IN88US=>	NF7nWG9USU6JUlXS
Daudi	NVG1TnhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHW4NJdKSzVyPUWuOlkyOiEQvF2=	NVnTZ3M6W0GQR2LFVi=>
NCI-H1648	NVXGUFVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTVwOEG0OVQh\|ryP	NYj1NHU4W0GQR2LFVi=>
OS-RC-2	MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPYTWM2OD13Lkm4OVk4KM7:TR?=	NEPuRYRUSU6JUlXS
DJM-1	Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHDfGc5UUN3ME22MlM1PjZ4IN88US=>	Mo\kV2FPT1KHUh?=
LS-1034	NIf2WXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37F[GlEPTB;Nj63OVY3KM7:TR?=	NG\jd4RUSU6JUlXS
NCI-H1581	M2PQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTZwN{i0NFUh\|ryP	MnniV2FPT1KHUh?=
UACC-257	MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkixTWM2OD15LkC0OVEzKM7:TR?=	M{\mNnNCVkeURWK=
KM-H2	MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfqb5RNUUN3ME23MlE5PDV5IN88US=>	NYnrUId1W0GQR2LFVi=>
NCI-H1436	M4H6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTdwNkm5N\|Ih\|ryP	NETkNlNUSU6JUlXS
IA-LM	M{H3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjtcHJNUUN3ME23Mlg2QSEQvF2=	MUXTRW5IWkWU
NCI-H526	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3f1OWlEPTB;OD6yOVY{PyEQvF2=	NGjMTFdUSU6JUlXS
GCIY	Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjKT3dJUUN3ME24MlM3QTZ3IN88US=>	NVrwSYdsW0GQR2LFVi=>
CP67-MEL	M4LPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\6TWM2OD16LkWzNlYh\|ryP	NVSzNZNEW0GQR2LFVi=>
KALS-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRThwOEO4OVEh\|ryP	MlXuV2FPT1KHUh?=
NCI-H1770	NXHnXYtwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPNO4pOUUN3ME24MlkxOjZ3IN88US=>	NUnmN2RpW0GQR2LFVi=>
8-MG-BA	NUXod3lMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzPOFZ2UUN3ME25MlMzQDR2IN88US=>	M2PmcXNCVkeURWK=
KY821	NEXpXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTlwN{e0PFQh\|ryP	NVn5TYdKW0GQR2LFVi=>
SNB75	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr6TWM2OD1zMD6wO\|Yh\|ryP	M4jmcnNCVkeURWK=
NCCIT	NH[0OGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1Hje2lEPTB;MUGuNFU5OiEQvF2=	MXXTRW5IWkWU
SJSA-1	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvGV3RKSzVyPUGxMlI5QTFizszN	NGHBPIRUSU6JUlXS
LB373-MEL-D	Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vDU2lEPTB;MUGuN\|gzPyEQvF2=	MVLTRW5IWkWU
TALL-1	M1\5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjHXHlKSzVyPUGxMlQxPThizszN	NV7KO\|REW0GQR2LFVi=>
NB69	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEP0[JlKSzVyPUGxMlc4ODVizszN	MYPTRW5IWkWU
NCI-H1355	NH6xSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1P2emlEPTB;MUGuPVQzPiEQvF2=	NIWwR2tUSU6JUlXS
DMS-153	NW[5WpJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGj1TmdKSzVyPUGyMlA1OjZizszN	M2G3Z3NCVkeURWK=
OPM-2	M1\kPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTF{LkG1PVYh\|ryP	NY\oSpRrW0GQR2LFVi=>
NB1	NVzVTXBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTF{LkK5JO69VQ>?	NVn0dVc4W0GQR2LFVi=>
A3-KAW	M3W3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fjPGlEPTB;MUKuN\|I{PiEQvF2=	MnezV2FPT1KHUh?=
NCI-H1882	NUTTVHZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPQTWM2OD1zMj60NFY3KM7:TR?=	MYTTRW5IWkWU
KG-1	M3:x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:4S5FKSzVyPUGyMlY2PDVizszN	MW\TRW5IWkWU
LC4-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrQOZpKSzVyPUGyMlc4ODZizszN	NE\iW5hUSU6JUlXS
HCE-T	NUexWWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzFRpVmUUN3ME2xN{4xODR7IN88US=>	NHn5WXhUSU6JUlXS
NEC8	NU\OVIlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoToTWM2OD1zMz6xNFM5KM7:TR?=	MX3TRW5IWkWU
IST-MEL1	M2nYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGOwTG9KSzVyPUGzMlU4QDhizszN	MXTTRW5IWkWU
EW-3	NXHm[W82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnDe4lKSzVyPUGzMlc1ODJizszN	Ml6zV2FPT1KHUh?=
CTB-1	MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTF2LkCzNlkh\|ryP	MYDTRW5IWkWU
LS-123	M1jX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTF2LkG1PFgh\|ryP	M3jDN3NCVkeURWK=
NCI-H1417	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTF2LkOwOVIh\|ryP	NUTyVYNNW0GQR2LFVi=>
MZ7-mel	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\hTWM2OD1zND60OFM{KM7:TR?=	MUnTRW5IWkWU
JiyoyeP-2003	M3jHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTF3Lk[zNlYh\|ryP	NEXsRYNUSU6JUlXS
ES6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;UOGVbUUN3ME2xOk4zOzZzIN88US=>	NXPzZXBUW0GQR2LFVi=>
HH	NInMe\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPWWZh3UUN3ME2xO{4yQTZ\|IN88US=>	NYLlN25bW0GQR2LFVi=>
SF539	M{H0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTF5Lkm5NlIh\|ryP	NFH5eGhUSU6JUlXS
Calu-6	NYTtUJZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTF7LkKzPUDPxE1?	NX;ncZk4W0GQR2LFVi=>
SK-MM-2	M1\0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XLT2lEPTB;MUmuOVU2KM7:TR?=	M1XHTXNCVkeURWK=
IST-MES1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjCTWM2OD1zOT62OlY{KM7:TR?=	MYrTRW5IWkWU
GI-ME-N	Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWniSG5yUUN3ME2xPU45OjJ5IN88US=>	NXvRN3VjW0GQR2LFVi=>
CAL-148	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHXUYpKSzVyPUKwMlk6OzRizszN	NVv6RYdNW0GQR2LFVi=>
EVSA-T	NH7zXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;YTWM2OD1{MT6xOFk6KM7:TR?=	MXLTRW5IWkWU
LP-1	NHjrfpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTOdGdRUUN3ME2yNU4{PDN{IN88US=>	NF7o[IlUSU6JUlXS
BOKU	NVi5V4J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTJzLkS1N\|Mh\|ryP	NIK5enVUSU6JUlXS
KLE	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTJ{LkG5NFMh\|ryP	NGHP[GJUSU6JUlXS
LB831-BLC	Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfR[5lKSzVyPUK1MlE2OjZizszN	MXvTRW5IWkWU
NCI-H889	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHNTWM2OD1{NT6xPVMyKM7:TR?=	NIK4U29USU6JUlXS
REH	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHkTWM2OD1{NT60OlcyKM7:TR?=	MXrTRW5IWkWU
KP-N-RT-BM-1	M4XZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnYTWM2OD1{NT60O\|UzKM7:TR?=	M2K0VXNCVkeURWK=
MPP-89	MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTJ3LkWzNVQh\|ryP	NEPMSItUSU6JUlXS
no-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTJ3Lke0O{DPxE1?	M4\2T3NCVkeURWK=
NCI-H748	M4nONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTJ3Lke2Nlch\|ryP	MU\TRW5IWkWU
LB2518-MEL	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrVPII3UUN3ME2yO{4yPzd\|IN88US=>	MYLTRW5IWkWU
TGBC1TKB	MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvPOW1SUUN3ME2yO{42PTh3IN88US=>	Mo\FV2FPT1KHUh?=
MHH-PREB-1	NWm2bWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2m3c2lEPTB;MkiuNFc{PCEQvF2=	NHfEfZRUSU6JUlXS
MZ2-MEL	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2T2V2lEPTB;MkiuOlE1OyEQvF2=	Mln6V2FPT1KHUh?=
U-266	M2HUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\N[JpZUUN3ME2yPE43OzZ4IN88US=>	M{PoSXNCVkeURWK=
SNU-C1	NGjxeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYD4[ldtUUN3ME2yPE46PDNizszN	M{jQbnNCVkeURWK=
SW962	M3zGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTNyLkK3OFch\|ryP	MorTV2FPT1KHUh?=
Raji	M2HYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTNyLkW1PVIh\|ryP	M{K4UHNCVkeURWK=
KNS-42	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPrTWM2OD1\|MD64PVU3KM7:TR?=	NVroO2p7W0GQR2LFVi=>
LB996-RCC	M{PFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfufYNKSzVyPUOxMlE4ODJizszN	MmjxV2FPT1KHUh?=
CHP-126	NH;ZN\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjadm9KSzVyPUOxMlE6QDRizszN	M2jINHNCVkeURWK=
RXF393	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3iOnR3UUN3ME2zNk41QTdizszN	NYHBd2xlW0GQR2LFVi=>
COLO-684	MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzSWG9KSzVyPUOyMlY1OzhizszN	NGDGRmVUSU6JUlXS
A704	NEG2RWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfBfGxKSzVyPUOzMlU2OzhizszN	NFfmNnRUSU6JUlXS
A253	M4fVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHPS2VKSzVyPUOzMlU5PTJizszN	NGPLXVlUSU6JUlXS
KNS-81-FD	NGHZPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELaTIJKSzVyPUO0MlU1PTZizszN	NWLNN2dHW0GQR2LFVi=>
TE-441-T	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDITWM2OD1\|ND62N\|cyKM7:TR?=	NXLMU4lLW0GQR2LFVi=>
HCC2157	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmP2TWM2OD1\|NT60OlE6KM7:TR?=	MYPTRW5IWkWU
ES3	NWnaV4NPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPVVJFHUUN3ME2zOk43PzVizszN	NYXFd3czW0GQR2LFVi=>
NCI-H1155	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDxV21vUUN3ME2zO{45OTVizszN	NYTpT\|ZoW0GQR2LFVi=>
SNU-C2B	NFTnT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nOO2lEPTB;M{iuNVY2PCEQvF2=	NX7XbZdrW0GQR2LFVi=>
JAR	NFzVdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLhTWM2OD1\|OD6yOFQ6KM7:TR?=	MYjTRW5IWkWU
GDM-1	NW[2dYo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTZTWM2OD1\|OD65NVE3KM7:TR?=	NFnnOI9USU6JUlXS
KU812	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjh[XJKSzVyPUSxMlUxPyEQvF2=	MoPaV2FPT1KHUh?=
BC-1	MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfyTWM2OD12Mj62O\|MyKM7:TR?=	MYXTRW5IWkWU
GI-1	M4izRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHyyNpRKSzVyPUSyMlkyQTJizszN	NVjkT5RUW0GQR2LFVi=>
NCI-H1694	NIH0dGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zvXmlEPTB;NESuPVQ4OiEQvF2=	MVzTRW5IWkWU
DG-75	NIPLWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlroTWM2OD12NT6xOVc4KM7:TR?=	MXzTRW5IWkWU
COR-L88	M{nSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjMVGZnUUN3ME20OU4zPzd6IN88US=>	Mn[0V2FPT1KHUh?=
LS-513	NX7wUndoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HVfmlEPTB;NEWuPVE2PiEQvF2=	MYTTRW5IWkWU
HD-MY-Z	NUTlO25ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fEUmlEPTB;NE[uOFYyOiEQvF2=	NVyxOI1rW0GQR2LFVi=>
L-363	NY[5dG86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\DbYF7UUN3ME20Ok45QDFizszN	NXf2PFFNW0GQR2LFVi=>
TE-6	NVrQN2R5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTR6LkS0OkDPxE1?	NXHIcFdkW0GQR2LFVi=>
NCI-H345	M4HYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;ydlN7UUN3ME20PE41PjhizszN	NETLbVdUSU6JUlXS
TE-5	MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrn[GxWUUN3ME20PU44OTF6IN88US=>	M{TzS3NCVkeURWK=

... Click to View More Cell Line Experimental Data

In vivo

VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. ^[1]

Protocol

Kinase Assay: ^[3]	+ Expand Kinase inhibition assays: The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl₂, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K _i = IC50 / (1 + [S]/K_d), where [S] = [ATP] = 2.2 mM, and K_d (of ATP to Abl) = 70 μM. These values are calculated assuming a K_d (ATP) of 70 μM for wild type and H396P Abl kinase domain.
Cell Research: ^[2]	+ Expand Cell lines: CAL-62 cells Concentrations: 5-500 nM Incubation Time: 4 days Method: The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500 nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500 nM). The cells are pulse labeled with 30 mM BrdU for 2 hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Female athymic NCr-nu mice bearing HL-60 leukemia cells Formulation: 50% PEG300 in 50 mM phosphate buffer Dosages: 50 mg/kg, 75 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Cheetham GM, et al. Cancer Lett. 2007, 251(2), 323-329.

+ Expand

Solubility (25°C)

In vitro	DMSO	93 mg/mL (200.17 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Molecular Weight	464.59
Formula	C₂₃H₂₈N₈OS
CAS No.	639089-54-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Pan Aurora Kinase Inhibitors

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
Pan Aurora Kinase Inhibitors

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
Most Potent Aurora Kinase Inhibitor

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
Aurora Kinase Inhibitor in Clinical Trial

Alisertib (MLN8237) : Phase III for Relapsed/Refractory Peripheral T-Cell Lymphoma.
Classic Aurora Kinase Inhibitor

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007), is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Features:First orally available inhibitor of Aurora A.
Barasertib (AZD1152-HQPA|AZD2811)

Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.
ZM 447439

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

Features:An Aurora selective ATP-competitive inhibitor.
MLN8054

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.
MK-5108 (VX-689)

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.
Aurora A Inhibitor I (TC-S 7010)

Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.

Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

Tozasertib (VX-680, MK-0457)

Cited by 53 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Choose Your Country or Region

By Signaling Pathways

By product type

Tozasertib (VX-680, MK-0457)

Cited by 53 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)